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Enteroviruses are RNA viruses found as commensals in the human gut and respira-
tory system, which may cause a wide spectrum of disease. Enteroviruses may cause
severe neurologic complications including acute flaccid paralysis (AFP) and encephali-
tis and are the most commonly diagnosed agents of viral meningitis. Outbreaks of
more severe disease are often associated with particular genotypes, such as
enterovirus-A71 causing rhombencephalitis and AFP. There are more than 300
described genotypes of human enterovirus, with overlaps in clinical phenotypes
between genotypes, and uncertainty about which genotypes are more prevalent in
neurological manifestations.
A systematic review of observational studies was conducted to evaluate the most
prevalent enterovirus genotypes causing AFP, encephalitis, and meningitis. The
genotyping methods and sampling sites were compiled as secondary outcomes.
Sources included MEDLINE, Embase (publications until January 2019), and refer-
ences selected from included studies. Meta-analyses using a random effects model
were performed to calculate the pooled proportion of enterovirus genotypes in each
disease.
Ninety-six publications met the eligibility criteria, comprising 3779 AFP cases, 1140
encephalitis cases, and 32 810 meningitis cases. Enterovirus-A71 was most fre-
quently associated with AFP (pooled proportion 0.12, 95% CI, 0.05-0.20) and
encephalitis (0.77, 95% CI, 0.61-0.91). Echovirus 30 (0.35, 95% CI, 0.27-0.42) was
the most predominant genotype in meningitis cases. Genotypes were most com-
monly determined using VP1 RT- reverse transcription-polymerase chain reaction,
and most samples assessed were cerebrospinal fluid.
With the emergence of enteroviruses as an increasing cause of neurological diseases,
surveillance and testing need to increase to identify the aetiology of the most com-
mon and most severe disorders.
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1 | INTRODUCTION
Human enteroviruses (EVs) are a genus of the Picornaviridae family
and responsible for a number of neurological conditions including
acute flaccid paralysis (AFP), encephalitis, and meningitis.1 They are
divided into four subgroups in humans based on their pathogenesis
and host range: Enteroviruses A through D.2 Polioviruses are classified
as part of the Enterovirus C species and have a well-defined pathoge-
nicity in the human central nervous system (CNS). However, due to
the success of poliovirus vaccination programs, there has been near-
global eradication of clinical poliomyelitis.3 The first nonpolio entero-
virus (NPEV) was discovered in 1948 when Dalldorf et al inoculated
newborn mice with faecal suspensions from suspected polio patients.4
The inoculation resulted in paralysis of the mice, and the causative
agent differed from poliovirus. This initially unclassified virus was
deemed the first member of the group A coxsackie viruses. Since then
there have been more than 300 genotypes of human NPEV identified
using new methods of molecular detection.5
Many studies focus on identifying the species and genotype of
NPEV that is implicated in an outbreak. For example, outbreaks of
aseptic meningitis in Europe within the last decade have been associ-
ated with echovirus 30.6 In comparison, enterovirus-D68 (EV-D68) is
thought to be linked to an upsurge of AFP cases across Northern
Europe and the United States in 2016.7 Enterovirus-A71 (EV-A71) is
known to be particularly neurovirulent and associated with fatalities,
particularly within the Asia-Pacific region.8 Typically, EV-A71 presents
with hand, foot, and mouth disease, which is a benign and self-limiting
condition. However, EV-A71 can also cause neurological infections
such as those discussed in this review, which can then have a severe
impact.8 For example, outbreaks of EV-A71 in Singapore resulted in
closure of schools to prevent ongoing transmission.9 Despite the
apparent predominance of certain EV genotypes in these diseases, the
associations between different EV genotypes have not been statisti-
cally compared in meta-analyses for AFP, encephalitis, and meningitis.
In response to the potential for EVs to inflict severe neurological
disease, the World Health Organization (WHO) considered NPEVs in
the WHO Research and Development Blueprint for the first time in
2018.10 NPEVs were deemed to require further research and devel-
opment after being classified as a major public health threat. This sys-
tematic review is timely given this update, and also because of the
ongoing development of vaccines. Phase III trials of an inactivated
vaccine against EV-A71 in Taiwan have demonstrated seroprotection
persisting for 2 years in most participants.11
NPEVs have been detected in different sites during episodes of
neurological conditions. In order to make a definitive diagnosis of viral
encephalitis or meningitis, CNS involvement needs to be confirmed,
such as by detection of virus in the cerebrospinal fluid (CSF).12 How-
ever, diagnosis may also be made when EVs are detected from other
sites including stool, serum, and throat swabs.13 Knowledge of which
sampling site is most commonly assessed and which sites are more
commonly positive may assist in the improvement of sampling
guidelines.
Traditionally, virus isolation and serology neutralization methods
were used for diagnosis of EVs, though these were time-consuming
and labour-intensive.14 Conventional immunological diagnosis
methods have been shown to be less specific than molecular assays
based on reverse transcription-polymerase chain reaction (RT-PCR)
targeting various genomic regions.15 The optimal target for EV detec-
tion and identification used to date has been VP1, which is a capsid
protein located at the virion surface.16 Two other structural proteins,
VP4 and VP2, have also been used for EV identification, though with
less success than VP1.16,17 However, before these structural proteins
were identified as targets, highly conserved sequences in the 50
untranslated region (50UTR) were amplified for EV RT-PCR and geno-
types imputed using sequencing. This method was later suggested to
be more suitable for detection of the presence of an NPEV rather
than genotyping.17 Given the proposed differences in sensitivity and
efficacy of these targets, we aimed to obtain an estimate of which
genotyping methods and targets are more prevalent across the
selected studies.
Previous reviews in this area have either focused on a single neu-
rological complication or have been limited geographically to one
country or region.18-21 The objective of this review was to conduct a
systematic search of the published literature to ascertain which NPEV
genotypes were globally most often diagnosed in cases of neurologi-
cal complications. Secondary objectives included recording the sam-
pling site and method of genotyping for these data.
2 | METHODS
2.1 | Literature search
Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines were followed in the reporting of this review.22
The completed PRISMA checklist is provided inTable S1.
Two reviewers (S. S. and S. S. B.) conducted a systematic search
for observational studies describing cases of NPEV AFP, encephalitis,
or meningitis, which identified specific genotypes of EVs. Databases
searched were MEDLINE and Embase from each database's date of
inception to 29 January 2019. The database search strategy was cre-
ated with a focus on terms for the virus and the terms for genotype.
These were combined with terms for any of the targeted diseases—
AFP, encephalitis, or meningitis. A combination of key words and rele-
vant subject headings specific to each database were also included
and listed in the full search strategy for MEDLINE in Table S2. No fur-
ther limits were applied. Finally, the reference lists of the chosen arti-
cles were screened manually to obtain more articles after title and
abstract exclusions.
2.2 | Inclusion criteria
Included studies were observational studies or surveillance reports
concerning patients diagnosed with AFP, encephalitis or meningitis
where specific genotypes of NPEV were identified from any sample
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site. No requirements were specified for the method of diagnosis
used; thus, each condition was recorded as reported by the author(s).
2.3 | Exclusion criteria
Exclusion criteria were as follows: (1) studies not presenting original
data or those in the form of letters, conference abstracts, and com-
ments; (2) studies that presented data in aggregate formats; (3) studies
that reported fewer than 10 NPEV samples or that genotyped less
than 50% of the NPEV-positive samples, and (4) studies limited to
high-risk populations such as immunodeficient patients. Where we
found multiple publications from one study, we selected only the
paper with the longest follow-up time or the largest sample size.
2.4 | Data abstraction
2.4.1 | Study selection
One author (S. S.) initially removed duplicate studies from the results
of the search. Two authors (S. S. and S. S. B.) then independently
screened the titles and abstracts of the remaining studies. This was
done with blinding of authors and journal titles, using a Microsoft
Excel workbook specifically designed for screening.23 Items for which
there was disagreement were discussed by the two screeners and
resolved by consensus. The full texts of the eligible studies were then
obtained and divided into English and non-English studies. Attempts
were made to find translations of non-English studies, but where this
was not possible, the non-English papers were not included in the
analysis. These studies are outlined in Table S3 with data extracted
from the abstracts. Authors of the English studies unable to be
obtained in full were contacted to request the manuscript. The
remaining English studies were assessed for eligibility with reasons for
exclusion detailed in Figure 1.
2.4.2 | Data extraction and quality assessment
We separated the final 96 studies into the three neurological
complications of interest: AFP,24-42 encephalitis,43-63 and
meningitis.26,48,56,58,64-119 The “encephalitis” category also
encompassed cases of rhombencephalitis, meningoencephalitis, and
studies that did not distinguish between meningitis and encephalitis.
As well as those patients explicitly diagnosed with AFP, patients
diagnosed as having “myelitis” were included in the “AFP” category.
Four studies included participants in two of the complication cate-
gories and were thus extracted separately in each category.26,48,56,58
The following five pieces of descriptive data were extracted into
three separate Microsoft Excel workbooks for each neurological con-
dition: (a) the citation of the study, (b) the country and the region des-
ignated by WHO that the study was conducted in, (c) the duration of
the study, (d) whether the study was prospective or retrospective, and
(e) whether the data were sourced from surveillance or hospital
records.
The primary outcome was documented as the total number of
NPEV positive samples, which were genotyped, including nontypable
samples and those that were only typed into species or not reported.
This was further divided into the number of samples allocated to each
genotype. If two methods of genotyping were used generating differ-
ent results, the one method with the higher number of successful
genotypes identified was included. If multiple specimens were positive
for the same viral genotype from one patient, they were recorded as
one case. Data were extracted from figures using WebPlotDigitizer
where needed.120 The following five secondary outcomes were col-
lected along with the descriptive data and primary outcomes in the
Microsoft Excel workbooks: (a) the site of sampling, (b) the age of par-
ticipants, (c) the method of genotyping used, (d) the method of diag-
nosis of the condition, and (e) whether the source of material
genotyped was isolated virus or nucleic acid direct from clinical
sample.
Where necessary, authors of the selected studies were contacted
via email to obtain missing data for the outcomes of interest. Authors
of 4/17 (23.53%) studies that were contacted provided additional
information.31,82,107,114
The quality of each selected article was scored according to the
Centre for Evidence-Based Medicine (CEBM's) levels of evidence ver.
2011.121 Disagreement in study appraisal was resolved by consensus.
2.5 | Data analysis
We conducted proportion meta-analyses with STATA 15.1 (StataCorp
LP, College Station, TX, USA) using the “metaprop” command for the
most common genotypes in each disease.122 The pooled proportion
was calculated with the total number of NPEV samples on which
genotyping was performed as the denominator. The Freeman-Tukey
variant of the arcsine transformation was applied to stabilize the vari-
ance of proportions.123 A random effects model was employed, as
there was significant heterogeneity anticipated given the nature of
observational studies.124 Confidence intervals (95% CI) were calcu-
lated using the DerSimonian and Laird method.125 We calculated the
I2 statistic as a measure of the proportion of the overall variation that
was attributable to between-study heterogeneity. Secondary out-
comes were assessed using descriptive statistics generated through
Microsoft Excel ver. 16.23 (Microsoft Corporation, Redmond, WA,
USA). Due to the small number of studies in each arm of analysis,
thorough subgroup analyses were not performed. However, we per-
formed preliminary subgroup analyses of four AFP33,37,39,41 and four
encephalitis49,51,56,62 papers, which genotyped nucleic acid direct
from clinical sample, to assess for laboratory method bias.
3 | RESULTS
3.1 | Results of literature search
An adapted PRISMA flow diagram shows the process followed to
select the studies used in this review (Figure 1).22 The initial search
yielded 1245 potential references, and three additional articles were
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obtained through hand searching of the bibliographies of included
studies. There were 96 articles published since 1962 included in this
systematic review. Four papers including data on two neurological
complications were recorded for both complications, generating a
total of 19 AFP studies, 21 encephalitis studies, and 60 meningitis
studies. In total, there were 37 729 patients: 3779/37 729 (10.02%)
AFP cases, 1140/37 729 (3.02%) encephalitis cases, and 32 810/37
729 (86.96%) meningitis cases. The majority of studies were from the
Western Pacific Region (30/96, 31.25%) or the European Region
(29/96, 30.2%).
A comparison of descriptive data for the three conditions is shown
in Table S4. For AFP, 10 studies24,31,34-36,38-42 used the WHO criteria
as a method of diagnosis, one study33 used separate criteria desig-
nated by a neurologist, and the remaining eight studies25-30,32,37 did
not report the criteria for diagnosis. Methods of diagnosis for cases of
encephalitis and meningitis were not consistently reported; thus,
these data were not collated.
Studies included in this review were eligible to be graded from
levels 1b to 4 of CEBM's five levels. Of the 96 studies, 67 (69.79%)
studies scored 2b or higher. The studies and corresponding CEBM
levels are listed in Tables 1–3 according to the three neurological
diseases.
3.2 | NPEV genotypes
The genotype distributions were analysed within each neurological
complication and are presented in Tables 4–6. Each proportion should
be considered as a pooled estimate of only those studies reporting
the particular genotype. Hence, cumulative point estimates do not
sum to 100%. Across AFP studies, EV-A71 was the most common
genotype detected, yielding a pooled proportion of 0.12 (95% CI,
0.05-0.20). Other common genotypes were echovirus 13 (0.08, 95%
CI, 0.05-0.12) and echovirus 11 (0.07, 95% CI, 0.05-0.09). For cases
of encephalitis, EV-A71 was also the most frequent virus detected,
(0.77, 95% CI, 0.61-0.91). This was followed by echovirus 30 (0.20,
95% CI, 0.03-0.44) and echovirus 18 (0.17, 95% CI, 0.00-0.53). In con-
trast, echovirus 30 was the most prominent genotype detected in
meningitis patients (0.35, 95% CI, 0.27-0.42). After echovirus 30,
echovirus 6 (0.13, 95% CI, 0.27-0.42) and echovirus 13 (0.13, 95% CI,
0.07-0.19) were most prevalent. The results of our preliminary sub-
group analyses in AFP and encephalitis papers, which genotyped
nucleic acid direct from clinical sample, demonstrated similar trends as
above. Across both AFP (0.47, 95% CI, 0.02-0.95) and encephalitis
(0.62, 95% CI, 0.19-0.96) studies, EV-A71 was the most predominant
virus detected in these analyses.
F IGURE 1 Search strategy
for the identification of studies
reporting which enterovirus (EV)
genotypes were prevalent in
acute flaccid paralysis,
encephalitis, and meningitis.
“Not relevant” included studies
focusing on diagnostics or
therapeutics, studies of
nonhuman EVs, evaluations of
surveillance studies, studies of
non-central nervous system
manifestations, studies on
polioviruses or other viruses,
studies on environmental samples
of EV exclusively, studies with
coinfections of other viruses,
papers on whole genome
sequencing of particular strains,
and single participant case studies
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3.3 | Secondary outcomes
All 96 studies reported method of typing and sampling site. These
data are presented in Table 7 and Figure 2. The most commonly used
method of genotyping was RT-PCR (80/96, 83.33%). The structural
protein VP1 was the most utilized RT-PCR target (44/96 studies,
45.83%). Only one included study published in 1998 used virus isola-
tion as a means of typing.92 The majority of the samples were CSF
alone or in addition to other samples (72/96 studies, 75.00%). Stool
was the next most prevalent sample type after CSF with 18/96 stud-
ies (18.75%) relying on stool samples alone.
4 | DISCUSSION
In this review, the most common NPEV associated with AFP and
encephalitis was EV-A71, and echovirus 30 was the most common
NPEV associated with meningitis.
4.1 | AFP genotypes
The most commonly identified genotypes in AFP cases after EV-A71
were echovirus 13 and echovirus 11. This is consistent with results
from another systematic review of AFP surveillance cases, which
found that the most commonly associated genotypes were EV-A71
(7.9%) and echovirus 11 (5.7%).18 In contrast, Suresh et al found that
in case reports and case series, EV-D68 was the next most prevalent
genotype after EV-A71. However, EV-D68 was not amongst the 10
most prevalent genotypes identified in the data presented here. This
may be explained by our exclusion of case reports and case series
involving less than 10 patients. Moreover, EV-D68 is most commonly
detected in respiratory specimens, and as demonstrated in our
review, most EV surveillance and outbreak programs used CSF or
stool as analyte.13 There have also been difficulties with EV-D68
detection due to cross-reactivity with rhinoviruses in various diag-
nostic settings.126 Thus, both sampling and laboratory biases may
have impacted the comparatively low proportion of EV-D68 in our
dataset.
This affects the issues surrounding EV-D68 detection and cau-
sality in neurological syndromes. The Centers for Disease Control
and Prevention (CDC) has reported a temporal association with EV-
D68 respiratory illness and acute flaccid myelitis (AFM) cases in the
United States, prompting ongoing surveillance.127 However, the lim-
ited detection of EV-D68 in neurological specimens has led to
TABLE 1 Characteristics of the studies included in the meta-analysis of AFP cases listed by WHO region
First Author, Year Study Period CEBM Level Cases, n Most Prevalent EV Genotype(s)
African Region
Oyero, 201424 N/A 3b 56 Echovirus 11
Sadeuh-Mba, 201325 2008-2009 2b 146 Coxsackie virus B1
Eastern Mediterranean Region
Bahri, 200526 1992-2003 3b 54 Coxsackie virus B3, echovirus 6
Shaukat, 201327 2010 1b 46 Echovirus 19
Angez, 201528 2013 2b 215 Echovirus 19
Shaukat, 201229 2009 3b 23 Echovirus 3, echovirus 11
Saeed, 200730 2003 1b 474 Echovirus 6
Angez, 201731 2003 2b 63 Coxsackie virus B5
European Region
Wieczorek, 201732 1999-2014 2b 16 Coxsackie virus B4
Region of the Americas
Sejvar, 201633 2014 2b 14 Enterovirus D68
South-East Asian Region
Laxmivandana, 201334 2009-2010 2b 422 Enterovirus-A76
Maan, 201335 2010 2b 54 Echovirus 13
Rao, 201236 2007-2009 3b 666 Enterovirus-A71
Western Pacific Region
Zhou, 201637 2010-2013 2b 26 Enterovirus-A71
Apostol, 201238 1992-2008 2b 386 Coxsackie virus A24
Tang, 201439 2006-2010 3b 98 Echovirus 13
Bingjun, 200840 1997-2004 2b 195 Echovirus 13
Tao, 201441 1988-2013 2b 792 Coxsackie virus B3
Kim, 201442 2002-2011 2b 33 Enterovirus-A71
Abbreviations: AFP: acute flaccid paralysis; CEBM: Centre for Evidence-Based Medicine; EV: enterovirus; WHO: World Health Organisation.
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debate regarding the role of the genotype in causing disease.128
Application of the Bradford-Hill criteria has supported a causal rela-
tionship between EV-D68 and AFM.128 Moreover, in 2017, an
experimental mouse model was inoculated with EV-D68, inducing a
paralytic disease resembling AFM.129 This model demonstrated all
of Koch's postulates, supporting the hypothesis that EV-D68 can
cause AFM. However, Koch's postulates have been revisited over
time in light of developments in virus diagnostics. In postulates
developed by Huebner, he considers the importance of tissue cul-
ture isolation; whereas Fredricks and Relman require sequence-
based evidence for microbial causation.130,131 This mouse model has
yet to satisfy these modified postulates of microbial pathogenesis
and thus requires further development to prove causality of EV-
D68 and AFM. This review suggests the need for more detailed
analysis of AFP cases where EV-D68 is detected. In addition, analy-
sis of respiratory specimens in cases of AFP, as introduced by the
CDC's surveillance, may allow for more sensitive detection of this
genotype.132
4.2 | Encephalitis genotypes
The most common EV genotypes identified in cases of encephalitis
were EV-A71, echovirus 30, and echovirus 18. This is consistent with
findings from the California Encephalitis Project in 1998 to 2005,
which is one of few large-scale surveillance studies compiling enceph-
alitis incidence data.133 In California, EVA-71 in particular was associ-
ated with severe illness, with two of the four fatalities in the
surveillance being attributed to EVA-71. This aligns with results from
our study demonstrating that EVA-71 was proportionally higher in
encephalitis rather than the typically less severe meningitis. At pre-
sent, there are limitations to studying the genetic determinants of the
genotype's neurovirulence. For example, there are restrictions con-
cerning existing animal models, as humans are the only natural host
for wild-type EV-A71 infection.134 A recent study successfully
infected NOD-scid IL2Rγ−/− (NSG) mice with human immune systems,
allowing insights into the human immune response to EV-A71 infec-
tion.135 This may provide a platform to evaluate EV-A71 therapies in
the future.
TABLE 2 Characteristics of the studies included in the meta-analysis of Encephalitis cases listed by WHO region
First Author, Year Study Period CEBM Level Cases, n Most Prevalent EV Genotype(s)
African Region
Schoub, 198543 1984 2b 10 Coxsackie virus B3
Eastern-Mediterranean Region
Dalwai, 200944 2003-2006 2b 29 Echovirus 9
European Region
Casas-Alba, 201745 2016 3b 50 Enterovirus-A71
Taravilla, 201946 2016 2b 18 Enterovirus-A71
Papa, 200947 2006-2007 3b 27 Echovirus 6
Region of the Americas
Tavakoli, 200848 2005-2006 2b 11 Coxsackie virus B3
South-East Asian Region
Singh, 201649 2011-2012 4 29 Echovirus 19
Kumar, 201150 2008 3b 15 Coxsackie virus B5
Kumar, 201251 2009-2010 1b 45 Echovirus 21
Kumar, 201352 2009-2010 4 31 Coxsackie virus B5, echovirus 3, Echovirus 6
Western Pacific Region
Zhang, 201353 2002-2012 4 233 Echovirus 30
Wei, 201654 2015 2b 26 Echovirus 30
He, 201355 2010 1b 33 Enterovirus-A71
Huang, 201556 2009-2013 2b 211 Enterovirus-A71
Ho, 199957 1998 2b 39 Enterovirus-A71
Chen, 201858 2013-2015 2b 97 Echovirus 18
Chen, 201059 2008 2b 15 Enterovirus-A71
B'Krong, 201860 1997-2010 1b 45 Enterovirus-A71
Ryu, 201061 2008-2009 2b 41 Enterovirus-A89
Wang, 201562 2012 2b 104 Enterovirus-A71
Yang, 200163 1998-1999 3b 31 Enterovirus-A71
Abbreviations: CEBM: Centre for Evidence-Based Medicine; EV: enterovirus; WHO: World Health Organisation.
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TABLE 3 Characteristics of the studies included in the meta-analysis of Meningitis cases listed by WHO region
First Author, Year Study Period CEBM Level Cases, n Most Prevalent EV Genotype(s)
African Region
Smuts, 201864 2015-2016 3b 29 Coxsackie virus A9
Wolfaardt, 201465 2010-2011 3b 30 Echovirus 4
Eastern Mediterranean Region
Othman, 201666 2011-2013 2b 21 Echovirus 4
Bahri, 200526 1992-2003 2b 19 Coxsackie virus B5
Meqdam, 200267 1999 2b 32 Echovirus 9
Dalwai, 201068 2003-2006 2b 92 Echovirus 9
Richter, 200669 2000-2002 2b 218 Echovirus 30
European Region
Vollbach, 201570 1998-2008 2b 14 Echovirus 30
Milia, 201371 2012 3b 10 Echovirus 30
Braunova, 201972 2012-2016 2b 67 Echovirus 30
Nougairede, 201473 2013 2b 119 Echovirus 30
Volle, 201474 2008-2012 1b 156 Echovirus 30
Chomel, 200375 2000 2b 116 Echovirus 13
Bottner, 200276 2000 3b 30 Echovirus 13
Logotheti, 200977 2007 2b 46 Echovirus 4
Frantzidou, 200778 2005 3b 11 Echovirus 5
Cabrerizo, 200879 2006 2b 116 Echovirus 30
Trallero, 200380 2000 2b 538 Echovirus 30
Ortner, 200981 1999-2007 2b 107 Echovirus 30
Wieczorek, 201582 2011-2014 2b 189 Echovirus 6
Druyts-Voets, 199783 1980-1994 2b 790 Echovirus 30
Brunel, 200884 2005 3b 51 Echovirus 30
Sensoy, 200985 1999-2004 2b 104 Echovirus 30
Dumaidi, 200686 2003-2005 3b 14 Echovirus 11
Siafakas, 200487 2001 2b 34 Echovirus 6
Sojka, 201188 2005-2009 2b 100 Coxsackie virus B4
Thoelen, 200489 1999-2002 2b 342 Echovirus 30
Cordey, 201790 2013-2015 2b 65 Echovirus 30
Holmes, 201691 2008, 2011-2014 3b 163 Echovirus 30
Atkinson, 199892 1975-1994 2b 24120 Echovirus 11
Trallero, 201093 1982-2007 2b 1544 Echovirus 30
Rudolph, 201794 2008, 2013 3b 196 Echovirus 30
Region of the Americas
Berlin, 199395 1986-1990 1b 161 Coxsackie virus B5
Julian, 200396 2001 2b 43 Echovirus 13
Dagan, 198897 1982-1983 2b 55 Echovirus 30
Karzon, 196298 1955 2b 127 Echovirus 6
Tavakoli, 200848 2005-2006 2b 39 Coxsackie virus B5
Peci, 201499 2005-2011 2b 583 Coxsackie virus A9
Luchs, 2008100 2004 3b 23 Echovirus 6
(Continues)
SURESH ET AL. 7 of 13
4.3 | Meningitis genotypes
The most common EV genotypes identified in cases of meningitis were
echovirus 30, echovirus 6, and echovirus 13. Echovirus 30 has been
responsible for numerous outbreaks in continents including
Asia103,112,117 and Europe,71,73,81 indicating an active global circulation
of this genotype. The predominance of echovirus 30 in cases of viral
meningitis has not been entirely explained, with research continually
being done into its mechanism of disease. In particular, Bernit et al
suggested that echovirus 30 transmission may not be strictly faecal-
oral as other NPEVs are, but this theory is yet to be substantiated.136
Consequently, as with EV-A71, the reasons for the neurovirulence of
echovirus 30 have yet to be comprehensively ascertained. Our review
thus confirms the importance of research into specific virulence fac-
tors and treatments in each of these prevalent genotypes.
4.4 | Genotyping method
The most common method of genotyping used was RT-PCR. The
structural protein VP1 was the target for RT-PCR amplification in
TABLE 3 (Continued)
First Author, Year Study Period CEBM Level Cases, n Most Prevalent EV Genotype(s)
South-East Asian Region
Kumar, 2013101 2009-2010 2b 51 Echovirus 32
Lee, 2007102 2005 3b 24 Coxsackie virus B5
Kim, 2012103 2008 3b 287 Echovirus 30
Joo, 2005104 1995-1999 3b 12 Coxsackie virus B1, echovirus 6, echovirus 30
Baek, 2011105 2008-2009 2b 16 Coxsackie virus B1
Hyeon, 2013106 1999-2011 2b 1063 Echovirus 30
Western Pacific Region
Momoki, 2009107 2004-2008 2b 24 Coxsackie virus B5
Cui, 2010108 2005 3b 15 Coxsackie virus A9
Liu, 2014109 2009 3b 16 Coxsackie virus B5
Kao, 2003110 2001 3b 17 Echovirus 30
Zhu, 2016111 2009-2010 2b 85 Echovirus 9
Xiao, 2013112 2012 2b 38 Echovirus 30
Tao, 2014113 2006-2012 2b 84 Echovirus 30
Kaida, 2004114 2001-2002 3b 36 Echovirus 13
Hsu, 2011115 2008 2b 19 Echovirus 30
Chen, 2013116 2009 2b 17 Coxsackie virus B5
Huang, 201556 2009-2013 2b 30 Enterovirus-A71
Chen, 201858 2013-2015 2b 54 Echovirus 18
Zhao, 2005117 2003 2b 18 Echovirus 30
Huang, 2003118 2000 2b 75 Echovirus 33
Papadakis, 2014119 2007-2012 2b 315 Echovirus 6
Abbreviations: CEBM: Centre for Evidence-Based Medicine; EV: enterovirus; WHO: World Health Organisation.
TABLE 4 Proportion of NPEV genotypes reported in the analyzed
AFP cases
Genotype Studies, n Proportion (95% CI) I2
Enterovirus-A71 11 0.12 (0.05-0.20) 96.62
Echovirus 13 12 0.08 (0.05-0.12) 90.17
Echovirus 11 12 0.07 (0.05-0.09) 78.9
Echovirus 6 12 0.06 (0.04-0.09) 87.94
Coxsackie virus B3 11 0.05 (0.03-0.09) 85.32
Coxsackie virus A24 7 0.05 (0.01-0.09) 92.96
Echovirus 7 12 0.04 (0.03-0.05) 59.77
Coxsackie virus B5 10 0.04 (0.02-0.06) 72.06
Echovirus 14 10 0.04 (0.02-0.06) 77.19
Echovirus 19 9 0.04 (0.02-0.06) 81.42
Other 18 0.6 (0.52-0.67) 94.16
Abbreviations: AFP: acute flaccid paralysis; NPEV: nonpolio enterovirus.
TABLE 5 Proportion of NPEV genotypes reported in the analyzed
encephalitis cases
Genotype Studies, n Proportion (95% CI) I2
Enterovirus-A71 10 0.77 (0.61-0.91) 93.45
Echovirus 30 5 0.20 (0.03-0.44) 95.72
Echovirus 18 3 0.17 (0.00-0.53) 93.8
Echovirus 6 6 0.13 (0.06-0.22) 77.82
Coxsackie virus B5 10 0.11 (0.05-0.18) 71.78
Other 20 0.53 (0.34-0.71) 97.26
Abbreviation: NPEV: nonpolio enterovirus.
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44/96 studies (45.83%). This is in line with recent recommendations
from the European NPEV Network that RT-PCR with VP1 should be
used for diagnosis of EV.17 After VP1, VP2, and VP4 are rec-
ommended as second-line targets of RT-PCR. The less frequent use of
50UTR in our results may be explained by the more conservative
nature of the 50UTR in comparison to the VP1 gene among EV spe-
cies.137 There has also been more genetic recombination found in the
50UTR region in comparison to the VP1 region.138 Both these issues
have been proposed to explain why a study conducted by Chiang et al
demonstrated more false positives and mismatched genotyping asso-
ciated with 50UTR than VP1 sequencing.,137,138 Moreover, the papers
included in our review did not utilize Next Generation Sequencing
methods. Currently, genome sequencing is a requirement for identifi-
cation of new recombination events and recombinant EVs, although it
is yet to be employed diagnostically on a large scale.17 In the future, it
is expected that sequencing methods will be readily used for diagnos-
tic EV typing in surveillance and outbreaks, especially as improve-
ments are made in cost and efficiency.17
4.5 | Limitations
The main benefit of performing this meta-analysis was the improved
power and precision gained by pooling estimates of genotype preva-
lence from individual studies. Our review included studies from all six
WHO regions, and 67.97% of included studies were rated 2b or
higher according to the CEBM criteria.
Nonetheless, this review poses a number of limitations. Firstly,
there is a risk of publication bias, due to the exclusion of both grey lit-
erature and conference abstracts that did not provide sufficient data
for analysis. We attempted to minimize this risk through a compre-
hensive literature search strategy and secondary hand-searching of
bibliographies from included studies. Secondly, the exclusion of non-
English studies from the meta-analyses may lead to language-bias. To
minimize this, we reviewed the non-English abstracts presented in
Table S3. Furthermore, the reliance on reported clinical diagnoses of
the neurological conditions may be associated with inaccuracies, as
there is often clinical overlap between encephalitis and meningitis.
TABLE 6 Proportion of NPEV genotypes reported in the analyzed
meningitis cases
Genotype Studies, n Proportion, 95% CI I2
Echovirus 30 41 0.35 (0.27-0.42) 98.74
Echovirus 6 36 0.16 (0.11-0.21) 96.37
Echovirus 13 23 0.13 (0.07-0.19) 96.95
Coxsackie virus A7 2 0.10 (0.10-0.10) 0.00
Echovirus 9 27 0.07 (0.05-0.09) 89.41
Coxsackie virus A9 22 0.07 (0.04-0.10) 90.14
Echovirus 11 20 0.07 (0.03-0.11) 98.25
Echovirus 18 16 0.06 (0.03-0.10) 92.55
Echovirus 7 12 0.03 (0.01-0.06) 98.04
Echovirus 19 3 0.03 (0.00-0.14) 98.92
Other 54 0.47 (0.42-0.53) 97.65
Abbreviation: NPEV: nonpolio enterovirus.
TABLE 7 Methods of EV genotyping across all 96 studies
Method of genotyping Number of studies
VP1 RT-PCR 44/96; 45.83%
MN assay and VP1 RT-PCR 12/96; 12.50%
MN assay 10/96; 10.42%
50UTR RT-PCR and VP1 RT-PCR 8/96; 8.33%
50UTR RT-PCR 5/96; 5.21%
IFA 6/96; 6.25%
VP1 RT-PCR and VP4 RT-PCR 3/96; 3.13%
MN assay, VP1 RT-PCR and 5'UTR RT-PCR 2/96; 2.08%
RT-PCR unspecified target 2/96; 2.08%
IFA,VP1 RT-PCR and 50UTR RT-PCR 1/96; 1.04%
VP2 RT-PCR 1/96; 1.04%
VP4/2 RT-PCR 1/96; 1.04%
Virus isolation 1/96; 1.04%
Abbreviations: EV: enterovirus; IFA: immunofluorescence assay; MN:
microneutralization; RT-PCR: reverse transcription-polymerase chain
reaction.
F IGURE 2 Site of sampling of specimens
across all 96 studies
SURESH ET AL. 9 of 13
Finally, it is possible that other neurotropic EVs, which are less easily
isolated or detected, may contribute to a greater degree than is appar-
ent in our review. This could also be influenced by the source of mate-
rial genotyped: isolated viruses or nucleic acid direct from clinical
sample. We were not able to perform extensive subgroup analyses in
this regard due to a restricted sample size, particularly in the isolated
viruses arm of analysis. However, brief subgroup analyses of four AFP
and four encephalitis papers, which genotyped nucleic acid direct
from clinical sample, revealed similar trends to the global analysis. It is
expected that more thorough diagnostic guidelines for EV neurologi-
cal complications and advancement in Next Generation Sequencing
will improve these limitations for future research in this subject area.
5 | CONCLUSIONS
This first meta-analysis of the global genotype distribution of EVs for
AFP, encephalitis, and meningitis shows that the predominant EV
genotypes differed between these conditions. Review demonstrated
that the most common genotypes were EV-A71 for AFP and encepha-
litis, and echovirus 30 for meningitis. This epidemiological knowledge
may assist in directing development in diagnostics and therapeutics
for EV neurological infections. Given the potentially severe outcomes
of such infections, attempts to characterize the neurovirulence of the
different genotypes must continue. This research will be aided by
development of Next Generation Sequencing techniques, more rigor-
ous surveillance programs, and advances in EV treatments and
vaccines.
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